Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development

Eman Saad Nassar; Yomna Abdelrazek Elkalbashawy; Ahmed Kamal; Nermine Hossam Eldin Zakaria

doi:10.5114/ceh.2021.104385

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2021
vol. 7

Send email

Copy url:

abstract:

Original paper

Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development

Eman Saad Nassar

¹

,

Yomna Abdelrazek Elkalbashawy

¹

,

Ahmed Kamal

²

,

Nermine Hossam Eldin Zakaria

¹

Clinical and Chemical Pathology, Alexandria University, Egypt
Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Egypt

Clin Exp HEPATOL 2021; 7, 1: 74-78

DOI: https://doi.org/10.5114/ceh.2021.104385

Online publish date: 2021/03/15

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Saad Nassar E, Abdelrazek Elkalbashawy Y, Kamal A, Hossam Eldin Zakaria N. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clinical and Experimental Hepatology. 2021;7(1):74-78. doi:10.5114/ceh.2021.104385.

APA

Saad Nassar, E., Abdelrazek Elkalbashawy, Y., Kamal, A.,  & Hossam Eldin Zakaria, N. (2021). Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clinical and Experimental Hepatology, 7(1), 74-78. https://doi.org/10.5114/ceh.2021.104385

Chicago

Saad Nassar, Eman, Yomna Abdelrazek Elkalbashawy, Ahmed Kamal,  and Nermine Hossam Eldin Zakaria. 2021. "Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development". Clinical and Experimental Hepatology 7 (1): 74-78. doi:10.5114/ceh.2021.104385.

Harvard

Saad Nassar, E., Abdelrazek Elkalbashawy, Y., Kamal, A.,  and Hossam Eldin Zakaria, N. (2021). Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clinical and Experimental Hepatology, 7(1), pp.74-78. https://doi.org/10.5114/ceh.2021.104385

MLA

Saad Nassar, Eman et al. "Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development." Clinical and Experimental Hepatology, vol. 7, no. 1, 2021, pp. 74-78. doi:10.5114/ceh.2021.104385.

Vancouver

Saad Nassar E, Abdelrazek Elkalbashawy Y, Kamal A, Hossam Eldin Zakaria N. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clinical and Experimental Hepatology. 2021;7(1):74-78. doi:10.5114/ceh.2021.104385.

PlumX metrics:

Aim of the study
Ultrasound surveillance for hepatocellular carcinoma (HCC) among cirrhotic patients is the currently used modality but it is operator dependent. Combining a tumor marker with ultrasound may improve sensitivity for early HCC detection. Our aim was to assess the galectin-3 level among HCC and cirrhotic patients on top of chronic hepatitis C to evaluate its possible role as a tumor marker for HCC surveillance among cirrhotic patients.

Material and methods
The study was conducted on 160 subjects. They were grouped as follows: group 1: 40 patients with HCC secondary to liver cirrhosis on top of chronic hepatitis C; group 2: 40 patients with cirrhosis secondary to chronic hepatitis C; group 3: 40 patients with chronic hepatitis C without advanced fibrosis; group 4: 40 healthy controls. Serum galectin-3 levels were determined in all subjects using ELISA.

Results
Serum galectin-3 level was significantly higher in HCC patients than in those with chronic hepatitis C (p < 0.001). Also it was significantly higher among cirrhotic patients than in patients with chronic hepatitis C (p < 0.001). But on comparing HCC patients with cirrhotic patients, serum galectin-3 levels were not significantly different (p = 0.926).

Conclusions
Galectin-3 levels cannot be used as an additional method for surveillance of HCC among cirrhotic patients.

keywords:

Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development

Eman Saad Nassar 1 , Yomna Abdelrazek Elkalbashawy 1 , Ahmed Kamal 2 , Nermine Hossam Eldin Zakaria 1

antiviral agents, liver cirrhosis, neoplasm recurrence

Eman Saad Nassar

¹

,

Yomna Abdelrazek Elkalbashawy

¹

,

Ahmed Kamal

²

,

Nermine Hossam Eldin Zakaria

¹